Product Insert

FUSION*Plex*™-HT Lung v2 panel

FUSION*Plex*-HT Lung v2

Description

The FUSION*Plex*-HT Lung v2 panel is a balanced pool of gene-specific primer (GSP) oligonucleotides that is optimized for use with FUSION*Plex*-HT reagents and molecular barcode (MBC) adapters to produce targeted NGS libraries. This product insert should be used in conjunction with FUSION*Plex*-HT protocol for Illumina® (RA-DOC-049).

FUSION*Plex*-HT Lung v2 contains **323** GSPs targeting **17** genes commonly mutated in non-small cell lung cancer (NSCLC).

Description	Part number	Storage
FUSION*Plex* Lung v2 GSP1, 24 reactions or FUSION*Plex* Lung v2 GSP1, 96 reactions	SA18090241 or SA18090961	–20°C ± 10°C
FUSION*Plex* Lung v2 GSP1, 24 reactions or FUSION*Plex* Lung v2 GSP1, 96 reactions	SA18090242 or SA18090962	
10X VCP Primer Mix	SA0126	

Recommended PCR cycling

	Step	Temperature (°C)	Time	Cycles
First PCR reaction	**1**	95	3 min	1
	2	95	30 sec	15
	3	60	10 sec	
	4	65	5 min (100% ramp rate)	
	5	72	3 min	1
	6	4	Hold	1

Recommended PCR cycling *(cont.)*

	Step	Temperature (°C)	Time	Cycles
Second PCR reaction	**1**	95	3 min	1
	2	95	30 sec	20†
	3	60	10 sec	
	4	65	5 min (100% ramp rate)	
	5	72	3 min	1
	6	4	Hold	1

†The number of PCR2 cycles may be decreased if you regularly experience library yields greater than 200 nM.

Recommended reads and multiplexing

FUSION*Plex*-HT Lung v2 libraries should be sequenced to a minimum of **1M** reads. Starting read depth recommendations for standard profiling may be adjusted based on user needs.

Archer™ Analysis settings

Sequencing data should be processed using Archer Analysis (v7, or greater). The FUSION*Plex*-HT Lung v2 panel requires selection of the ***Fusion*** pipeline and (optional) ***SNV/Indel*** pipeline, found under the ***RNA*** Input Type. See the Archer Analysis User Guide for more details on setting up your analysis.

Processing of FUSION*Plex*-HT Lung v2 libraries requires a one-time upload of the Custom Panel GTF. Files can be obtained by contacting archer-tech@idtdna.com.

Assay targets

Gene	Accession	Exon	Variant Type	Description**
ALK	NM_004304	2, 4, 6, 8, 10, 12, 14, 16, 17, 18, 19, intron19, 20, mid-exon20, 21, 22, 23, 26	Fusion, ALK ATIV, Internal deletion (ALKΔ2-17, ALKΔ2-3)	5'
ALK	NM_004304	1, 2	Internal deletion (ALKΔ2-17, ALKΔ2-3)	3'
ALK	NM_004304	22, 23, 25	Mutation	p.P1153-p.C1156, p.F1174, p.L1196-p.S1206, p.G1269

Gene	Accession	Exon	Variant Type	Description**
BRAF	NM_004333	2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 15, 16	Fusion, Kinase Domain Duplication, BRAFΔ2-10, BRAFΔ4-10, BRAFΔ2-8, BRAFΔ3-8, BRAFΔ4-8	5'
BRAF	NM_004333	1, 2, 3, 7, 8, 10, 13, 14, 18	Fusion, Kinase Domain Duplication, BRAFΔ2-10, BRAFΔ4-10, BRAFΔ2-8, BRAFΔ3-8, BRAFΔ4-8	3'
BRAF	NM_004333	15	Mutation	p.V600
EGFR	NM_005228	7, 8, 9, 14, 15, 16, 17, 18, 19, 20	Fusion, Exon 2-7 Skipping (EGFRvIII), Kinase Domain Duplication	5'
EGFR	NM_005228	1, 24, 25, mid-exon25, 26	Fusion, Exon 2-7 Skipping (EGFRvIII), Kinase Domain Duplication	3'
EGFR	NM_005228	18, 19, 20, 21	Mutation	p.E709-p.G719, p.E746-p.L760, p.V774-p.G796, p.L858-p.L861
ERBB2	NM_004448	4, 5, 13, 15, 17	Fusion, Exon 16 skipping (Δ16HER)	5'
ERBB2	NM_004448	15, 23, 24, 25, mid-exon26, 26	Fusion, Exon 16 skipping (Δ16HER)	3'
ERBB2	NM_004448	8, 20	Mutation	p.G309-p.S310, p.Y772-p.P780, p.C805
FGFR1	NM_015850	2*, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17	Fusion, Kinase Domain Duplication	5'
FGFR1	NM_015850	12, 17	Fusion, Kinase Domain Duplication	3'
FGFR1	NM_023110	4, 13, 14	Mutation	p.T141, p.V561, p.K656
FGFR2	NM_000141	2*, 3, 5, 6, 7, 8, 9, 10	Fusion	5'
FGFR2	NM_000141	16, 17, 18	Fusion	3'
FGFR2	NM_000141	7, 9, 12, 13, 14	Mutation	p.S252-p.P253, p.G305, p.Y375-V395, p.I547-p.N549, p.V564, p.A648-p.K659

Gene	Accession	Exon	Variant Type	Description**
FGFR3	NM_000142	3, 5, 8, 9, 10, 11, 12, 13, 14	Fusion	5'
FGFR3	NM_000142	16, 17, intron17, mid-exon18	Fusion	3'
FGFR3	NM_000142	7, 9, 13, 14, 16	Mutation	p.R248-p.S249, p.G370-p.R399, p.V555, p.D641-p.K650, p.G697-p.K715
KRAS	NM_004985	2, 3, 4	Mutation	p.G12-p.G13, p.Q61, p.K117, p.A146
MET	NM_000245	2, 4, 5, 6, 13, 14, 15, 16, 17, 21	Fusion, Exon 14 Skipping (METΔex14)	5'
MET	NM_000245	2, 13	Fusion, Exon 14 Skipping (METΔex14)	3'
NRG1	NM_001159996	1*, 3, 4, 5	Fusion	5'
NRG1	NM_004495	1, 2, 3, 4, 5, 6	Fusion	5'
NRG1	NM_013958	1*	Fusion	5'
NRG1	NM_013959	1*, 3	Fusion	5'
NRG1	NM_013962	1*	Fusion	5'
NRG1	NM_013962	1	Fusion	3'
NTRK1	NM_001007792	1, 2	Fusion	5'
NTRK1	NM_002529	1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14	Fusion	5'
NTRK1	NM_002529	13, 14, 15, 16, 17	Mutation	Full kinase domain coverage for resistance mutations including p.G595
NTRK2	NM_006180	4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18	Fusion	5'
NTRK2	NM_006180	11, 14	Fusion	3'
NTRK2	NM_006180	16, 17, 18, 19, 20, 21	Mutation	Full kinase domain coverage for resistance mutations

Gene	Accession	Exon	Variant Type	Description**
NTRK3	NM_001007156	15	Fusion	5'
NTRK3	NM_002530	3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16	Fusion	5'
NTRK3	NM_002530	13, 14, 15, 17	Fusion	3'
NTRK3	NM_002530	15, 16, 17, 18, 19	Mutation	Full kinase domain coverage for resistance mutation detection including p.F617, p.G623, p.G696
NUTM1	NM_175741	2*, 3, mid-exon3, 4, 5, mid-exon6, 6	Fusion	5'
PIK3CA	NM_006218	2, 15	Fusion	5'
PIK3CA	NM_006218	2, 3, 5, 6, 8, 10, 14, 21	Mutation	p.E81K-p.G118D, p.L339-p.D350, p.G364R, p.E418-p.C420, p.E453-p.K468, p.P539-p.Q546, p.E726, p.Y1021-p.T1052
RET	NM_020630	2, 4, 6, 8, 9, 10, 11, mid-exon11, 12, 13, 14	Fusion	5'
RET	NM_020630	15, 16	Mutation	p.A883, p.M918
ROS1	NM_002944	2, 4, 7, 31, 32, 33, 34, 35, 36, 37	Fusion	5'
ROS1	NM_002944	38	Mutation	p.G2032

*Indicates exons that are entirely untranslated region (UTR), or for which the UTR is targeted.

**The mutations listed under the Description column are targeted by the assay design. Version 6.2 and earlier of Archer Analysis may not support RNA SNV/Indel variant calling at exon junctions depending on the sequence context (SNVs ≤5bp, indels ≤30bp). *De Novo* RNA SNV/Indel and Internal Tandem Duplication mutation detection are not supported on the Ion Torrent Sequencing System.

ᵞALK-ATI currently requires review outside of Archer Analysis.

Limitations of use

For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

Safety data sheets pertaining to this product are available upon request.

Revision History

Document Number	Date	Description of change
RA-DOC-450/REV01	October 2023	Initial release.
RA-DOC-450/REV02	November 2023	Updated First and Second PCR cycling conditions to include separate anneal and extended steps. Updated branding.